|
Board of Directors
Robert Hiam, HMSA. Mr. Hiam is the President and
Chief Executive Officer of the Hawaii Medical Services
Association (HMSA), which is a Blue Cross/Blue Shield
affiliated insurer and Hawaii’s largest health care
plan. Mr. Hiam holds the Board seat elected by Tissue
Genesis Series A Preferred shareholders. He has extensive experience
in the medical insurance industry and advises Tissue
Genesis on issues regarding reimbursements, healthcare
costs and industry strategies. Mr. Hiam has served
as Chairman and/or Director of Blue Cross and Blue
Shield Association, Western Conference of Prepaid
Medical Service Plans, Aloha United Way, The Blood
Bank of Hawaii, Children’s Discovery Center, D.A.R.E
Hawaii, Hawaii Business Roundtable, Hawaii Employers
Council and Pacific Health Research Institute.
Michael Ruley. Michael Ruley holds the Board seat elected by the Series B Preferred shareholders. Mr. Ruley is the Chief Executive Officer of Sparkplug, Inc. He brings to the Board extensive experience in business and corporate finance. Mr. Ruley had served as the Chief Executive Officer of Hawaiian Telcom, an independent telecommunications company based in Honolulu, Hawaii, providing wireline, wireless, long distance, yellow pages. Mr. Ruley had also served as President and Chief Executive Officer of NextiraOne, and in several senior positions at XO Communications and Teleport Communications Group. He serves on the Board of Directors for Allied Bioscience Services, Inc. and as a member of the Young Presidents’ Organization International. He previously served as a trustee for the Hawaii Pacific University, a director of the Blood Bank of Hawaii, Child and Family Service, Hawaii Business Roundtable, USS Missouri Memorial Association, Inc. and the United States Telecom Association, and as a member of the Japan-Hawaii Economic Council, Hawaii Asia Pacific Association, and the Executive Committee of USTelecom.
Jeff Watanabe, Esq., Watanabe Ing, LLP. Mr. Watanabe is a retired partner of the Honolulu law firm of Watanabe Ing he helped found in 1971. Mr. Watanabe remains active as a business and community leader serving on the boards of Alexander & Baldwin and its subsidiary, Matson Navigation Company, Cellular Bioengineering, Inc., First Insurance Company of Hawaii, Grace Pacific Corporation, Oahu Publications (The Honolulu Star-Advertiser and MidWeek), and Trex Enterprises. He chairs the board of Hawaiian Electric Industries and is a board member of HEI subsidiaries American Savings Bank and Hawaiian Electric Company. Mr. Watanabe’s work with non-profits includes being a trustee of Sesame Workshop in New York and chairing the Consuelo Foundation headquartered in Honolulu and Manila.
Anton C. Krucky, Tissue Genesis
Thomas F. Cannon, Tissue Genesis
|
|
Management
Tissue Genesis has a strong corporate management team,
covering scientific and technical aspects, as well as
business management, capital raising and strategic partner
transactions. In addition, Tissue Genesis has built a
world class science and technology development team, consisting
of top young scientists in the field of tissue engineering
and regenerative medicine.
Tissue
Genesis Code of Conduct
Corporate Management Team
Anton C. Krucky, Co-Founder, Director, President
and Chief Executive Officer.Mr. Krucky co-founded Tissue Genesis Inc., in 2001. Mr. Krucky has decades of management experience that include product development, marketing, and sales for IBM. Prior to leaving IBM, he served as General Manager of Pacific Operations. He is a director at Servco Pacific, Inc., a privately held company and advisor board member for Oceanic Time Warner Cable and Farmers Insurance Hawaii. In addition he is a director for numerous community organizations including the Cancer Research Center at the University of Hawaii.
Thomas F. Cannon, Co-Founder, Director, Executive Vice President, Research and Development. Mr. Cannon is a co-inventor of
the Bio-Optimization System, a co-founder of Tissue
Genesis and the former President/founder of Bio-Optima.
As a former program manager and space hardware developer
for the highly successful Cell Culture Module (CCM)
experiments series for NASA, Department of Defense,
and NIH, he pioneered early versions of the BOS systems
fourteen Space Shuttle missions in the 1990’s. He
has extensive experience working with military hospitals,
and has an established network of government contacts,
medical contacts and bioengineering industry connections.
Mr. Cannon is responsible for bringing together key
technology assets and relationships with technology
providers, leading researchers, and end users to TGI.
Rex Chang, M.D., Director of Business Development. Dr. Chang has expertise and training in the life sciences and healthcare sectors. Prior to joining Tissue Genesis, Dr. Chang consulted in the healthcare sector in emerging markets and did many years of legal work for global life science companies. Dr. Chang is a trained attorney, and physician. Dr. Chang received his J.D. degree from the Boalt Hall School of Law at UC Berkeley, and his M.D. degree from New York University’s School of Medicine, where he also trained in Radiology. Dr. Chang also earned an accelerated M.B.A. degree from U.S.C.’s Marshall School of Business. Dr. Chang earned his undergraduate degree in biology at The Johns Hopkins University. Dr. Chang is licensed to practice law in California and New York.
Science and Technology Development Team
Stuart Williams, Ph.D., Chief Science Officer. Dr. Williams is Scientific Director of the Cardiovascular Innovation Institute at the University of Louisville School of Medicine. He is recognized internationally as an expert in vascular biology and vascular tissue engineering, and is a leader in endothelial cell isolation technology. He developed and patented the technique of isolating human endothelial cells and pluripotent stem cells from fat tissue obtained through liposuctions, currently licensed by Tissue Genesis through Thomas Jefferson University.
Gary D. Gentzkow, M.D., Chief Medical Officer. Dr. Gentzkow heads the company’s efforts to move its research programs in adipose (fat) derived cells into clinical studies. Dr. Gentzkow has 30 years experience developing new medical therapies – pharmaceutical, medical devices, biological and cellular. For the past 20 years, Dr. Gentzkow’s research has focused on cellular therapies, including engineered human tissues, a field in which he has lectured and published extensively. This work has focused on wound healing and cardiovascular regeneration and repair, and he has been a consultant to companies developing these new technologies. From 1992 to 2006, at Advanced Tissue Sciences and Smith & Nephew, Dr. Gentzkow headed the clinical research programs for the tissue-engineered human tissues, Dermagraft® and TransCyte®, dermal tissues approved for diabetic foot ulcers and burns respectively. He also participated in research programs on cartilage, blood vessels, and cardiovascular regeneration. Dr. Gentzkow is also the CMO for Theregen, Inc., conducting clinical studies utilizing this tissue-engineered human tissue technology, under the name of Anginera™, for cardiac regeneration. Additionally, his work has included clinical studies on antiarrhythmic drugs, fibroblast growth factor for venous stasis and diabetic ulcers, and electrical stimulation for healing pressure ulcers. He has published numerous articles and presented extensively in the field of wound healing and cardiovascular medicine around the world. Dr. Gentzkow received his A.B. degree cum laude from Harvard University and earned his M.D. degree from the University of Oregon Health Sciences Center and trained in Internal Medicine.
Paul Kosnik, Ph.D., Vice President, Research and Development, and Principal Investigator. Dr. Kosnik is Tissue Genesis’ Principal Investigator
for Federal Grants and leads the Tissue Genesis team
in innovations of proprietary intellectual property.
His research and development efforts have been focused
on tissue engineering and biochamber design, specifically
hardware, software and instrumentation that emulate
in vivo environments for medical applications of cell
and tissue culture products. He has received four
patents in the fields of tissue engineering and biochamber
design and has authored five peer-reviewed manuscripts
and three book chapters on functional tissue engineering.
Dr. Kosnik is a member of the Tissue Engineering Society
International and the International Society for Cellular
Therapy. He serves as an adjunct assistant professor
at Brown University, a visiting scientist in the Harvard-MIT
Division of Human Sciences and Technology and is a
member of the External Advisory Board for the University
of North Carolina at Chapel Hill.
Kevin Lye, M.D., Director, Clinical Research. Dr. Lye leads the efforts of Tissue Genesis to develop the product interface and methodology for clinicians—from varied disciplines—who use the company's technology. Exploration of, and application to, new fields of use also play a large role in his responsibilities. Dr. Lye comes to Tissue Genesis with ten years of experience in post-graduate training, including a research fellowship at Yale University. He has authored or co-authored over 25 publications on topics including novel therapies for carcinoid disease, refrozen botulinum toxin efficacy, abdominal wound closure devices, and gastric stem cells. Dr. Lye is privileged to have previously worked in the laboratories of James D. Otvos, Ph.D., founder of LipoMed, Inc.; Louis Argenta, M.D., inventor of negative pressure wound therapy devices used worldwide to heal complex wounds; and Irvin M. Modlin, M.D., Ph.D., a widely renowned innovator and director of the Gastric Pathobiology Research Group at Yale. He has been an invited speaker to multiple international conferences, and over 60 presentations relating to his research projects have been made around the world in various venues. After receiving his undergraduate degrees summa cum laude from North Carolina State University, including B.S. degrees in mathematics, biochemistry, and biological sciences, as well as a B.A. in chemistry, Dr. Lye earned his M.D. degree from the Wake Forest School of Medicine and an M.B.A. with distinction from Hawai`i Pacific University.
H. Joon Paek, Ph.D., Scientist. Dr. Paek is an expert in cell
replacement therapy for diabetes and cartilage degeneration.
He will lead the company’s research and development
in regenerative cell-based medicine, with special
focus on ligaments and diabetes. He received his Ph.D.
in Biology from Brown University, a Masters of Engineering
in Polymer Chemistry from Kyoto University in Japan,
and his undergraduate degree in Chemistry from the
College of William and Mary.
Michelle Stein, Ph.D., Scientist. Dr. Stein, with expertise in cell biology, molecular biology, and biochemistry focuses on technical writing and biomedical research toward our vascular and ligament project efforts. Dr. Stein received her PhD in biomedical science from the Medical University of South Carolina and Bachelor of Science from Virginia Commonwealth University. She has held such appointments as Visiting Scholar at University of California, San Diego as well as an Adjunct Faculty position at Coastal Carolina University. She is currently a member of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) and the International Fat Applied Technology Society (IFATS).
Erik Vossman, Director of Product Development. Mr. Vossman is the co-inventor of the mini-BOS, the Tissue Genesis Cell Isolation System, and pre- and post-processing peripherals. He provides product development expertise from concept to manufacturing to regulatory submission, as well as supply chain management. A graduate of the University of Michigan’s bioengineering program, he brings advanced biology and engineering expertise to the present and emerging Company systems.
|
|
